Understanding Obscure GI Bleeding
Approximately 300,000 hospitalizations that occur annually are due to OGIB and many of those may be attributed to readmission as well. GI Bleeding can be a mystery; diagnosis should not be. When it comes to obscure GI Bleeding, getting an accurate diagnosis can be a challenge. Endoscopy can provide clues, but the source of the bleeding may remain a mystery. This independent study module will explore diagnostic options and the role of endoscopic therapy in early diagnosis, leading to early treatment of Obscure GI Bleeding (OGIB)
This learner-paced activity is intended primarily for RNs with a responsibility for or an interest in obscure GI bleeding. The presentation will also be of interest to allied healthcare personnel and MDs involved in endoscopy.
Upon completion of this presentation, participants will be able to:
- Identify three causes of obscure GI bleeding and the various diagnostic and treatment modalities.
- Describe Iron Deficiency Anemia
- Discuss various aspects of patient teaching
- Contrast the diagnostic tools used for OGIB.
Participants will complete the web-based learning activity. They will read the article, then register to take the post-test and complete the evaluation on the website. They will submit the documentation as directed. A bibliographic reference is included for those wishing additional information.
Upon completion of the entire program, achieving a score of 80% on the post-test, and submission of required documentation, participants will be granted 1 contact hour. No partial credit will be granted.
Provider approved by the California Board of Registered Nursing, Provider Number 08747, the District of Columbia Board of Nursing, Provider Number 50-574, the Florida Board of Registered Nursing, Provider Number 50-574, the Georgia Board of Nursing, Provider Number 50-574 and the West Virginia Board of Examiners for Registered Professional Nurses, Provider Number 50-26112.
It is the responsibility of the licensee to verify acceptance of contact hours for relicensure.
NCCT: This program is acceptable for surgical technologist recertification by National Center for Competency Testing
- Successful completion: Participants will read the module, then register online, achieve a score of 80% on the post-test and submit required documentation. An active printer connection is required to print the certificate of completion.
- Conflict of interest: Planners disclose no conflict of interest. The subject matter experts disclose salary or honorarium from the commercial support entity; they have signed a statement agreeing to present material fairly and without bias
- Commercial company support: Fees are underwritten by education funding provided by Medtronic.
- Non-commercial company support: None.
- Alternative/Complementary therapy: None.
Participants successfully completing the activity and submitting required documentation will be permitted to print a certificate of completion. Participants are advised to retain the certificate for eight years following activity completion.
Replacement of misplaced certificate is available from Educational Dimensions. There is a fee for this service. Request a replacement by contacting Educational Dimensions.
Guide to Study
The following steps will assist you in your successful completion of this eLearning Activity.
- Read the content or view the recorded presentation. If you want contact hours at the completion of studying the eLearning material, you will be required to register, complete an evaluation and take a post-test prior to printing your Certificate of Completion. We urge you to complete the eLearning activity once you have started. However, if you do need to come back later, you can sign in with your email and eLearning ID.
- First Time Visitors will be asked to register using an email address as your User Name. Make a note which email address you have used. Then you will create an eLearning ID using a combination of at least 6-10 letters or numbers. Please make a note of your eLearning ID and if for some reason you forget, you may request that your eLearning ID be sent to you. The web site is secured by Trustwave.
- Return Visitors: If you have registered already you do not need to register again. Just Sign In using your email and eLearning ID.
- Evaluation Form: Once you have registered or signed in you will be asked to complete an evaluation form and submit it. This is required to obtain the Certificate of Completion.
- Post-test: A post-test, based on the content of the eLearning activity, will need to be taken. A passing score of 80% is required. This is required to obtain the Certificate of Completion.
- Printing Your Certificate of Completion: Once you have successfully passed the post-test you will be able to print your Certificate of Completion. You will be given an opportunity to verify the information that will be printed on your certificate. Please make sure your printer is ready to print. You will not have access to the certificate page on later visits unless you contact us. Once you choose to print the Certificate of Completion, it will not be possible to make corrections. To obtain a corrected certificate you will need to contact Educational Dimensions. Fees may apply.
- If you encounter any technical problems during this eLearning activity, please contact us.
Understanding Obscure GI Bleeding
Obscure GI bleeding (OGIB) has been defined as overt or occult bleeding of unknown origin that persists or recurs after an initial negative bidirectional endoscopic evaluation including ileocolonoscopy and EGD. Overt OGIB refers to visible bleeding (i.e. melena or hematochezia), whereas occult OGIB refers to cases of fecal occult blood positivity and/or unexplained iron deficiency anemia. Recent advances in small-bowel imaging, including video capsule endoscopy (VCE), angiography, and device assisted enteroscopy (DAE), have made it possible to identify a small-bowel bleeding source and therefore manage the majority of patients who present with OGIB. As a result, a recent clinical guideline recommends a shift from the term obscure GI bleeding to small-bowel bleeding. The term OGIB would be reserved for patients in whom the sources of bleeding cannot be identified anywhere in the GI tract after completion of comprehensive evaluation of the entire GI tract, including the small bowel (ASGE, 2017). Approximately 300,000 hospitalizations that occur each year are due to OGIB and many of those may be attributed to readmissions as well.
Types of OGIB
There are two classifications for obscure GI bleeding: overt and occult. Overt bleeding is the term used when blood is visible. Types of overt bleeding include melena (black, tarry stools), hematemesis (vomiting of blood) and hematochezia (passage of fresh blood n or with stool). Overt bleeding patients are generally those admitted to the hospital for evaluation of active bleeding. If a patient presents with an upper GI bleed with hematemesis, an urgent EGD should be performed. If the patient presents with lower GI bleeding, symptoms of hematochezia or melena, a colonoscopy should be performed.
The term “occult small bowel bleeding” can be reserved for patients presenting with iron deficiency anemia (IDA), with or without guaiac-positive stools, who are found to have a small bowel source of bleeding. Of all the sources of GI bleeding, only a small percentage (5%) is attributed to small-bowel sources. In occult bleeding, blood is NOT visible. Occult gastrointestinal bleeding usually is discovered when fecal occult blood test results are positive, or iron deficiency anemia is detected. The initial work-up for occult bleeding typically involves colonoscopy or esophagogastroduodenoscopy, or both. In patients without symptoms indicating an upper gastrointestinal tract source, or in patients older than 50 years, colonoscopy usually is performed first.
Iron Deficiency Anemia
Iron Deficiency Anemia (IDA) is often associated with OGIB. If a patient presents with IDA, it is important to identify what is causing the anemia. Other factors that may lead to IDA include serum iron blood loss. IDA can occur with Crohn’s disease, small bowel tumors, ulcerative disease, cancers and long-‐term use of aspirin, ibuprofen or arthritis medicines.
Although symptoms of IDA can be mild, patients may experience a change in mood, a sense of weakness or fatigue, headaches or problems concentrating. For patients who present with IDA, physicians generally will manage the deficiency with an iron therapy medication. The physician will continue to monitor the patient to observe how they are responding. If a patient is not responding to therapy, finding the cause of the anemia can help provide better long-term patient outcomes.
Patients with blood loss and iron deficiency anemia who have a negative workup on standard examinations require comprehensive evaluation. Once findings on upper and lower endoscopy prove negative, the small bowel may be assumed to be the source of blood loss.
The three major causes of intestinal bleeding are:
- Ulceration: a sore that develops on the lining of the esophagus, stomach or small intestine caused when stomach acid damages the lining of the digestive tract. Common causes of ulcers include bacteria H. Pylori and nonsteroidal anti-inflammatory pain relievers (NSAIDS), aspirin and Crohn’s disease. Upper abdominal pain is a common symptom of ulcers.
- Lesions (such as Angiectasias and Neoplasms): Angiectasias of the small bowel account for 20% to 30% of small-bowel bleeding and are more commonly seen in older patients. These lesions are painless. Patients often present with heme-positive stools or modest amounts of bright red blood from the rectum. Bleeding is often intermittent, sometimes with long periods between episodes. Patients with upper GI lesions may present with melena. Major bleeding is unusual.
- Tumors: Small-bowel tumors (i.e. GI stromal tumors, carcinoid tumors, lymphomas and adenocarcinomas) can present with small-bowel bleeding in both younger and older patients. Gastrointestinal stromal tumors (GISTs) are tumors that form in the digestive tract — most often the stomach or upper part of the small intestine. GISTs begin in nerve cells that signal the digestive organs to contract, causing food to move through the digestive tract so that it can be digested and processed. GISTs can form anywhere in the digestive tract, including the esophagus, stomach, pancreas, small intestine, appendix, colon, rectum. GISTs can be cancerous (malignant) or noncancerous (benign).
In approximately 5% of the bleeding patient population, the source is found in the small intestine.
There are many other causes of gastrointestinal bleeding, which are classified into upper or lower, depending on their location in the GI tract.
Upper GI Bleeding
- Peptic ulcers: open sores that develop on the inside lining of the stomach and the upper portion of the small intestine. The most common symptom is stomach pain. Peptic ulcers include gastric ulcers (occur on the inside of the stomach) and duodenal ulcers (occur on the inside of the upper portion of the small intestine). Common causes of peptic ulcers are infection with bacterium Helicobacter pylori and long-term use of aspirin and NSAIDS
- Gastritis: an inflammation, irritation or erosion of the lining of the stomach. It can be classified as acute or chronic, depending on the speed of onset. Common causes are irritation due to excessive alcohol use, chronic vomiting, stress or the use of certain medications, such as aspirin or NSAIDS.
- Esophageal varices: abnormal, enlarged esophageal veins that occur most often in people with serious liver disease. They develop when normal blood flow to the liver is blocked by a clot or scar tissue in the liver. To go around the blockages, blood flows into smaller blood vessels that aren’t designed to carry large volumes of blood. The vessels can leak blood or even rupture, causing life-threatening bleeding.
- Inflammation of the GI lining from ingested materials
- Certain GI cancers
Lower GI Bleeding
- Diverticulitis: caused by small, bulging pouches (diverticula) that can form in the lining of the digestive system. Diverticula are often found in the lower part of the large intestine. When one or more of the pouches become inflamed or infected, symptoms can include severe abdominal pain, fever, nausea and a marked change in bowel habits.
- Inflammatory Bowel Disease (IBD): involves chronic inflammation of all parts of the digestive tract. IBD primarily includes ulcerative colitis and Crohn’s disease. Both involve severe diarrhea, pain, fatigue and weight loss. IBD can be debilitating and can lead to life-threatening complications.
- Infectious diarrhea: diarrhea due to an infectious etiology, often accompanied by symptoms of nausea, vomiting or abdominal cramps. It can be categorized as acute (less than 14 days) or persistent (greater than 14 days).
- Angiodysplasia: most common vascular lesion of the GI tract. Vessel walls are thin with little or no smooth muscle, and the vessels are distended) and thin. It is a degenerative lesion of previously healthy blood vessels found most commonly in the cecum and proximal ascending colon. It is the most common vascular abnormality in the GI tract and after diverticulosis, it is the second leading cause of lower GI bleeding in patients older than 60 years.
- Polyps: growths that form on the lining of the colon. Possible symptoms are rectal bleeding, change in stool color, change in bowel habits, pain, nausea, vomiting and iron deficiency anemia.
- Hemorrhoids: engorged veins in the lowest part of the rectum and anus. Sometimes the walls of these blood vessels stretch so thin that the veins bulge and get irritated, especially during a bowel movement. They are caused by a build-up of pressure in the lower rectum that can affect blood flow and make the veins swell.
- Anal fissures: tears in the lining of the lower rectum (anal canal) that cause pain during a bowel movement. Anal fissures can be caused by injury or trauma to the anal canal.
- Gastrointestinal cancers
The goals of the physician treating the OGIB patient include stabilization, followed by locating and identifying the cause of the bleeding. Frequently, bleeding will stop and start, making it difficult to locate by any diagnostic means. Therefore, it is critical to find the source early in the evaluation process. This is substantiated in a retrospective study by Dr. Aman Singh, et. al. This study analyzed the diagnostic yield of capsule endoscopy (CE) in patients who underwent the procedure for OGIB within three days of admission, as compared to patients who underwent CE in a timeframe greater than three days after admission. A total of 144 patients were included in the analysis. Overall, positive findings were detected in 65.9% of patients, including bleeding, AVMs (arteriovenous malformations), ulcers, red spots, tumors and non-small bowel findings. In patients who underwent CE within three days of admission, the diagnostic yield for active bleeding or an AVM was found to be 44.4%. In patients who underwent CE after three days of admission, the diagnostic yield for active bleeding or an AVM was found to be 27.8%.
Therapeutic intervention was successful in 18.9% of patients evaluated within three days, as compared with 7.4% of patients evaluated after three days. The average length of stay in patients evaluated within three days of admission was 6.1 days, as compared with 10.3 days in the group evaluated after three days of admission. Timing of video capsule endoscopy is important for patients presenting with GI bleeding, with optimal diagnostic yields and therapeutic outcomes when the procedure is done sooner rather than later.
Discussion points with a patient can include (but are not limited to):
- Gastrointestinal (GI) bleeding is not a disease, but a symptom of a disorder in the digestive tract.
- Although the blood often appears in stool or vomit, it isn’t always visible. It may cause the stool to look black or tarry.
- The level of bleeding can range from mild to severe and life-threatening.
- Bleeding in the stomach or colon can usually be easily identified but finding the cause of bleeding that occurs in the small intestine can be difficult.
- Sophisticated imaging technology can usually locate the problem and minimally invasive procedures often can fix it.
Diagnostic Tools Used for OGIB
There are many diagnostic tools which can facilitate the physician’s diagnosis. These are outlined in the following table, along with “pro and con” considerations for each.
|CTA (computed tomography angiography)||
|CTE (computed tomography enterography)||
|SBFT (small bowel follow through/enteroclysis)||
|Tagged red blood cell scan||
|Video Capsule Endoscopy||
|Crohn’s Video Capsule Endoscopy||
Suggested Flow for Diagnosing OGIB
The American College of Gastroenterology (ACG), the American Gastroenterological Association (AGA) and the American Society for Gastrointestinal Endoscopy (ASGE) all suggest following a protocol to manage patients. Generally, the hospital will first exhaust their available endoscopic tests, which most likely will not reach the small bowel. If upper and/or lower endoscopies are negative, radiologic examinations will likely be recommended.
Next, facilities may use deep enteroscopy, CT enterography, CT angiography, capsule endoscopy, push enteroscopy, repeat colonoscopy and tagged red blood cell scintigraphy to find the source of bleeding. Ultimately, the institution and MD will determine the next step. Because these tests are complementary, a combination may be required to find the active bleeding.
The following flowchart will illustrate the decision process.
The American College of Gastroenterology (ACG), the American Gastroenterological Association (AGA) and the American Society for Gastrointestinal Endoscopy (ASGE) have guidelines for diagnosing Obscure GI Bleeding.
The American College of Gastroenterology (ACG) Guidelines includes an exhaustive list of recommendations for managing OGIB. But the first one that stands out is the recommendation that Video Capsule Endoscopy be implemented as first-line evaluation of the small bowel over radiology examinations. This paper suggests that patients be considered to have “small bowel bleeding” after a negative upper and lower endoscopy, and only be considered to have obscure GI bleeding following a full small bowel examination.
Here are some excerpts from the guidelines:
- Video Capsule Endoscopy (VCE) should be considered as a first line procedure for small bowel investigation, after a negative upper and lower endoscopy.
- Video Capsule Endoscopy should be performed before double balloon enteroscopy to increase diagnostic yield if there is no contraindication.
- In patients with occult hemorrhage or stable patients with active overt bleeding a capsule endoscopy procedure should be performed prior to CT (computed tomography)
- Barium studies should not be performed in the evaluation of small bowel bleeding
- CTE (computed tomographic enterography) should be performed in patients with suspected small bowel bleeding and a previously negative capsule endoscopy (strong recommendation)
- CT is preferred over magnetic resonance (MR) imaging for the evaluation of suspected small bowel bleeding
- CTE should be performed in patients with suspected obstruction prior to capsule endoscopy or in patients with known IBD
- The ACG 2015 guideline proposed the term “small bowel bleeding” as a replacement for the previous classification of obscure GI bleeding (OGIB).
The American Gastroenterological Association’s (AGA) position on obscure GI bleeding is that patients with occult blood loss and/or iron deficiency anemia, who have a negative workup on EGD and colonoscopy, need comprehensive evaluation, including a small bowel evaluation by capsule endoscopy, to identify an intestinal bleeding lesion. When all findings on EGD and colonoscopy are negative, the small bowel may be assumed to be the source of blood loss.
The American Society of Gastrointestinal Endoscopists’ (ASGE) position on obscure GI bleeding states that in patients with OGIB, Video Capsule Endoscopy should be the first diagnostic tool for the small bowel if no contradictions exist. VCE should be the first diagnostic tool in the evaluation of the small bowel in patients with OGIB, based on the institutional experience and availability. Small bowel follow-through should be considered of limited value in the evaluation of GI bleeding.
The general approach to the treatment for patients with obscure bleeding is similar to treatment for any patient with active bleeding. That is, patients should be managed aggressively, with serial hemodynamic monitoring and careful resuscitation. Intensive care monitoring with aggressive resuscitation is important, since it may decrease mortality. Appropriate endoscopic, angiographic, medical or surgical intervention should be instituted.
For lesions found within the reach of a standard endoscope, treatment includes the appropriate therapy, such as electrocautery, argon plasma coagulation, injection therapy, mechanical hemostasis (hemoclips or bands) or a combination of these techniques.
More distal vascular lesions in the small bowel, such as angiectasias, may be approached for therapy through push enteroscopy or deep enteroscopy, depending upon location. Evidence shows that treatment has a positive impact on clinical outcome by decreasing blood loss and need for blood transfusions.
Masses or tumors likely require surgical intervention or intraoperative enteroscopy. Management of massive bleeding should be coordinated with surgery and interventional radiology.
Essentially, a lesion in any site of the gastrointestinal tract can bleed in an occult or obscure fashion. The most common manifestation of occult bleeding is a positive fecal occult blood test (FOB) or iron deficiency anemia (IDA). While gastrointestinal tract malignancy is a crucial consideration in this group of patients, bleeding is most often caused by ulcerative disease of the upper gastrointestinal tract. The most common cause of obscure bleeding is vascular ectasia, which is difficult to manage, unless a specific bleeding lesion can be identified. Routine endoscopy is important in these patients, particularly to search for rare lesions, or more common lesions with an unusual or atypical appearance. In patients who have a lesion that is not within reach of standard upper endoscopy or colonoscopy, VCE and deep enteroscopy can allow access to the small bowel. Thus, these techniques have an important role in the diagnostic approach to bleeding in these patients. Effective treatment of patients with occult or obscure bleeding is predicated on the identification of a specific bleeding lesion. When it comes to diagnosing obscure GI bleeding, timing matters. The earlier the diagnosis, the better the chances of successful treatment.
Getting an accurate diagnosis with capsule endoscopy within the first three days of admission dramatically increases the rate of successful therapeutic intervention. Further research is expected to shed light on the role of CE and deep enteroscopy, particularly whether these modalities improve outcomes.
- ASGE Standards of Practice Committee: Gurudu SR et al. The role of endoscopy in the management of suspected small-bowel bleeding. Gastrointestinal Endoscopy 2017, (85) 22-31.
- ASGE. American Society of Gastrointestinal Endoscopy (2010). The role of endoscopy in the management of obscure GI bleeding. Gastrointestinal Endoscopy 72(3): 471-479.
- Bull-Henry K & Al-Kawas FH. (2013). Evaluation of Occult Gastrointestinal Bleeding. American Family Physician 87(6):430-436.
- Gasia V & Lamendola O. (2017). Diulafoy’s Lesion - An Uncanny Etiology of Gastrointestinal Bleed. The Journal of The Louisiana State Medical Society: Official Organ of The Louisiana State Medical Society, 169(2), 50. Retrieved from http://search.ebscohost.com/login.aspx?
- Gerson L et al. (2015). ACG Clinical Guideline: Diagnosis and management of small bowel bleeding. American Journal of Gastroenterology 110:1265-1287.
- Gralnek IM. (2005). Obscure-overt gastrointestinal bleeding. Gastroenterology. 128(5): 1424-30.
- Kim G, Soto JA & Morrison T. (2018). Radiologic Assessment of Gastrointestinal Bleeding. Gastroenterology Clinics of North America, 47(3), 501–514. https://doi.org/10.1016/j.gtc.2018.04.003
- Koffas A, Laskaratos FM & Epstein O. (2018). Non-small bowel lesion detection at small bowel capsule endoscopy: A comprehensive literature review. World journal of clinical cases, 6(15), 901-907.
- Min YW & Chang DK. (2016). The Role of Capsule Endoscopy in Patients with Obscure Gastrointestinal Bleeding. Clinical Endoscopy, 49(1), 16–20.
- Raju GS et al. (2007). American Gastroenterological Association (AGA) Institute Medical Position Statement on Obscure Gastrointestinal Bleeding. Gastroenterology 133(5):1694-1696.
- Raju GS et al. (2007). American Gastroenterological Association (AGA) Institute Technical Review on obscure gastrointestinal bleeding. Gastroenterology 133(5):1697–1717.
- Rockey DC. (2010). Occult and obscure gastrointestinal bleeding: causes and clinical management. National Reviews, Gastroenterology & Hepatology 7(5): 265-279.
- Sealock RJ, Thrift AP, El-Serag HB & Sellin J. (2018). Long-term follow up of patients with obscure gastrointestinal bleeding examined with video capsule endoscopy. Medicine, 97(29), e11429.
- Sheba E, Farag A, Aref W et al. (2017). Double-balloon enteroscopy (DBE) in patients presenting with obscure gastrointestinal bleeding (OGIB). Arab Journal of Gastroenterology: The Official Publication Of The Pan-Arab Association Of Gastroenterology, 18(4), 228–233.
- Singh A et al. (2013). Timing of video capsule endoscopy relative to overt obscure GI bleeding: implications from a retrospective study. Gastrointestinal Endoscopy 77(5): 761-766.